Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial-Reference-Cited by-同舟云学术

Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial

Published:2021-08 Issue: Volume:178 Page:108984
ISSN:0168-8227
Container-title:Diabetes Research and Clinical Practice
language:en
Short-container-title:Diabetes Research and Clinical Practice

Author:

Della Pepa Giuseppe,Russo Marco,Vitale Marilena,Carli Fabrizia,Vetrani Claudia,Masulli Maria,Riccardi Gabriele,Vaccaro Olga,Gastaldelli Amalia,Rivellese Angela A.,Bozzetto Lutgarda

Funder

Italian Medicines Agency

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference39 articles.

1. Nonalcoholic fatty liver disease: a systematic review;Rinella;JAMA,2015

2. Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis;Mantovani;Diabetes Care,2018

3. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms, and pharmacological implications;Targher;Gut,2020

4. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels;Portillo-Sanchez;J Clin Endocrinol Metab,2015

5. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis;Younossi;J Hepatol,2019

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the mechanisms of hepatogenous diabetes and its therapeutic perspectives;Life Sciences;2024-09

2. Sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors on major liver outcomes in metabolic dysfunction‐associated steatotic liver disease;Diabetes, Obesity and Metabolism;2024-08-12

3. Nano-drug delivery systems (NDDS) in metabolic dysfunction-associated steatotic liver disease (MASLD): current status, prospects and challenges;Frontiers in Pharmacology;2024-08-06

4. Review of current and new drugs for the treatment of metabolic-associated fatty liver disease;Hepatology International;2024-06-08

5. Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology;Atherosclerosis;2024-05